Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04749745 · ClinicalTrials.gov registry record · Early Phase 1

Effects of L-theanine on Motor Cortex Excitability in Healthy Subjects: A Paired-Pulse TMS Study

A Early Phase 1 study, sponsored by Butler Hospital.

Completed
Registry status
Early Phase 1
Development phase
11
Enrollment target

NCT04749745 is a Early Phase 1 study that has completed, run by Butler Hospital. The registered enrollment target is 11 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04749745, a Early Phase 1 study, has completed, sponsored by Butler Hospital.

COMPLETED
Registry status
Early Phase 1
Development phase
11 participants
Enrollment target

Study Summary

Major depressive disorder (MDD) is a serious mental illness and the leading cause of disability worldwide. New pharmacotherapeutic agents with complementary neurobiological mechanism and better side effect profile are of great needs. In addition to the monoamine system, the glutamatergic system plays a crucial role in MDD. L-theanine (N5-ethyl-L-glutamine) is the primary psychoactive component uniquely in green tea. Preclinical studies have demonstrated anti-depressant effect of L-theanine in rodents and provided evidences for its pharmacological properties of N-methyl-D-aspartate (NMDA) and gamma-aminobutyric acid (GABA) agonism. Yet these effects have not been proven in humans. Only one open-label clinical trial has studied and supported antidepressant effects of L-theanine in MDD patients. We propose using pair-pulse transcranial magnetic stimulation (ppTMS) to probe how L-theanine may manipulate the glutamatergic and GABA systems in the frontal region by changing cortical excitability first in healthy subjects. We plan to investigate the neurobiological effects of L-theanine in healthy subjects first. Granted that the first phase pilot trial provides neurophysiological evidence of L-theanine on motor cortex excitability in human subjects, next phases of studies on L-theanine in MDD patients cortical excitability could be justified.

Interventions

  • DRUG Placebo
  • DRUG L-theanine

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2020-06-09
Est. Completion 2021-05-31
Phase Early Phase 1

Sponsor

Butler Hospital

103 total trials

What the Registry Record Tells You About NCT04749745

The ClinicalTrials.gov registry entry for NCT04749745 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Butler Hospital, which has 103 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT04749745 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04749745 about?

NCT04749745 is a clinical study titled "Effects of L-theanine on Motor Cortex Excitability in Healthy Subjects: A Paired-Pulse TMS Study". Major depressive disorder (MDD) is a serious mental illness and the leading cause of disability worldwide. New pharmacotherapeutic agents with complementary neurobiological mechanism and better side effect profile are of great needs. In addition to the monoamine system, the glutamatergic system play...

What is the current status of trial NCT04749745?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 11 participants. The study started on 2020-06-09. Estimated completion is 2021-05-31.

What interventions are being tested in trial NCT04749745?

The interventions under investigation include: Placebo (DRUG), L-theanine (DRUG).

Who is sponsoring clinical trial NCT04749745?

This trial is sponsored by Butler Hospital, which has 103 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.